ERBB2 and breast cancer: In a recent study, 246 patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative BC were randomized to receive standard neoadjuvant chemotherapy with/without zoledronate, administered three-weekly for six cycles.